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Abstract  
Dysregulated inflammation is a central pathological process in diverse disease 
states. Traditionally, therapeutic approaches have sought to modulate the pro- or 
anti-inflammatory limbs of inflammation, with mixed success. However, insight into 
the pathways by which inflammation is resolved has highlighted novel opportunities 
to pharmacologically manipulate these processes, which might represent a 
complementary (and perhaps even superior) therapeutic approach. This review 
discusses the state of the art in the biology of resolution of inflammation, highlighting 
the opportunities and challenges for translational research in this field. 
 
Introduction 
The past 20 years have afforded greater clarity about Celsus’ four cardinal signs of 
inflammation — namely, calor (heat), dolor (pain), rubor (redness) and tumor 
(swelling) — and how they might be reversed or resolved. Arising from these 
advances, it has been proposed that some diseases that are associated with chronic 
inflammation may be underpinned by dysregulated resolution as much as driven by 
ongoing pro-inflammatory processes, and that therapy based on rectifying these 
defects will help guide ongoing inflammation down a pro-resolution pathway..  
 
Pro-resolution strategies intrinsically afford greater scope than conventional anti-
inflammatory approaches; however, despite our burgeoning understanding of 
resolution biology, clear limitations remain. Pharmacologically tackling the fifth 
cardinal sign — functio laesa (loss of tissue function) — is challenging. Equally, just 
as inflammation onset follows many diverse courses, resolution pathways are 
heterogeneous, with evidence to date suggesting they are probably tissue- and 
stimulus-specific. Thus, although central cellular and molecular mediators may be 
elucidated, it is unclear whether any one pro-resolution regimen will act as a 
panacea for multiple disease states.  
 
In this Review, we provide an update on the field of inflammation and resolution, 
describing the key cellular players, and the factors that regulate their phenotype, fate 
and clearance. We then describe recent evidence that effective resolution represents 
a bridge between innate and adaptive immunity. Moreover, we introduce the idea 
that diseases characterized by chronic inflammation may be associated with 
‘frustrated resolution’, whereby the inability to adequately resolve acute inflammation 
leads to maladaptive immunity. Finally, we highlight efforts to target pro-resolution 
pathways in diseases involving inflammation and models in which such strategies 
are investigated. We wish to provoke a re-think on how chronic inflammation is 
addressed therapeutically; arguing that the development of novel pro-resolving 
agents may be as beneficial as, and perhaps synergistic with or superior to, the 
administration of anti-inflammatory drugs. 
 
Normal and ‘frustrated’ resolution  
Recent evidence indicates that, following normal inflammation and resolution, a third 
phase known as post-resolution occurs, in which the affected tissue develops 
adaptive immunity. Here, we briefly describe inflammation, normal resolution and 
post-resolution, and suggest that in certain situations chronic inflammation may 
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represent a case of ‘frustrated resolution’ where the goal of achieving adaptive 
immunity is not met.  
 
Inflammation. Inflammation is a protective reaction of the microcirculation, initiated 
after infection and/or injury. Local and systemic inflammatory responses both aim to 
eliminate the inciting stimulus, promote tissue repair and healing and, in the case of 
infection, establish immune memory such that the host mounts a faster and more 
specific response on a future encounter.  
 
The acute inflammatory response is a complex yet highly coordinated sequence of 
events involving molecular, cellular and physiological alterations. It begins with the 
production of soluble mediators (including complement; chemokines; cytokines; 
eicosanoids, such as prostaglandins; free radicals; and vasoactive amines) by 
resident cells — (that is, tissue macrophages, dendritic cells (DCs), lymphocytes, 
endothelial cells, fibroblasts and mast cells) in the injured or infected tissue. 
Concomitantly, cell adhesion molecules are upregulated on circulating leukocytes 
and endothelial cells, promoting promote the exudation of proteins and influx of 
granulocytes from the blood. This well-characterized phase of the inflammatory 
response is routinely targeted using drugs such as non-steroidal anti-inflammatory 
drugs (NSAIDs) and pro-inflammatory cytokine-negating biologics (for example, 
tumour necrosis factor (TNF)-specific antibodies) that inhibit or antagonise the action 
of these mediators, and currently form the mainstay for the treatment of chronic 
inflammatory disease.  
 
Upon arrival, these leukocytes (typically polymorphonuclear cells (PMNs) in the case 
of non-specific inflammation or eosinophils in response to allergens) primarily 
function to phagocytose and eliminate tissue debris and microorganisms through 
distinct intracellular mechanisms (for example, involving superoxide radicals, 
myeloperoxidase, proteases and lactoferrins) and/or extracellular mechanisms (such 
as neutrophil extracellular traps). The type of effector cells, number of cells and 
ability of these effector cells to neutralize the inciting stimuli probably signal the next 
phase of pro-resolution processes.  
 
Resolution. The period between peak inflammatory cell influx and their clearance 
from the tissue site and restoration of functional homeostasis — that is, classically 
defined resolution — is no longer considered a passive event during which 
inflammation simply fizzles out1, 2. Instead, a complex, tightly regulated, cascade of 
processes occur. First, the injurious agents that triggered the inflammatory response 
are eliminated. Subsequently, the synthesis of pro-inflammatory mediators is 
suspended, and any such mediators that remain are catabolised, stopping further 
leukocyte recruitment and oedema formation. Next, regardless of whether the initial 
response was PMN- or eosinophil-driven or adaptive to re-call antigens (lymphocyte 
mediated), immune cells are cleared from the tissue. Inflammatory leukocytes can 
re-enter systemic circulation, but many influxed PMNs, eosinophils and lymphocytes 
undergo local apoptosis or necrosis and subsequent efferocytosis by recruited 
monocyte-derived macrophages (MDMs). Multiple intricate signalling mechanisms 
and factors control each of these processes and the balance between them, 
including cell-to-cell receptor binding and humoral mediators, particularly bioactive 
lipids. Once efferocytosis is complete, macrophages can leave the inflamed site by 
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lymphatic drainage; however, evidence also suggests that a small population may 
undergo local apoptosis3.  
 
Post-resolution. Recently, we demonstrated that classical resolution may not be the 
end of the local immune response; rather, there is a third phase that we termed post-
resolution4. Traditionally, resolution processes were deemed successful if acute 
inflammation was terminated; however they may have a hitherto unappreciated role 
in controlling adaptive immune responses and maintaining tolerance. Specifically, we 
found that following the resolution of murine innate-immune responses to a low dose 
of Saccharomyces cerevisiae cell wall extract (zymosan; administered 
intraperitoneally (i.p.)) or ovalbumin-labelled Streptococcus pneumoniae (also i.p.), 
there was a previously overlooked second influx of leukocytes into tissues that 
persisted for weeks (Fig. 1a). These cells comprised three separate populations of 
Ly6chi (bone marrow-derived) MDMs, including CD11B+;CD49d+;CD115+;MHC-II+ 
myeloid-derived suppressor cells (MDSCs); F480lo;MHC-II+;CD11c+ DCs; and 
F480int/CD11Bhi/CD11c– macrophages. In addition, tissue-resident (embryonic-
derived) macrophages, which disappeared during the acute inflammatory response, 
re-appeared. These diverse populations of macrophages were observed alongside 
lymph node expansion and increased numbers of memory T and B lymphocytes in 
the peripheral blood and tissue. PMNs were not observed in the affected tissues 
during this phase. Based on our studies and the work of others5-8, we concluded that 
DCs residing in naive tissues take up antigens and migrate to local lymph nodes to 
stimulate the initial steps in T-cell activation. As inflammation resolves, however, we 
found that Ly6chi monocyte-derived macrophages and/or DCs — either from the 
resolving site or from peripheral blood — further amplify the adaptive arm of the 
response while tissue-resident macrophages preferentially phagocytose apoptotic 
PMNs4, 9. These Ly6chi monocyte derived macrophages remain in tissues for months 
after inflammation has resolved, and help to dictate the magnitude and duration of 
subsequent acute innate inflammatory responses4, 10.  
 
As these observations were not seen when resolution was disrupted (Fig. 1b), we 
suggest that local pro-resolution processes help bridge innate and adaptive 
immunity4 (Fig. 1a,2). Thus, resolution could be redefined as the creation of a tissue 
microenvironment that facilitates interaction between the innate and adaptive arms of 
the immune system4. Indeed, examples exist to support this idea: for one, 
inflammatory adjuvants typically aid vaccine efficacy11. Traditionally, adjuvants were 
thought to act as a depot from which the antigen was slowly released, enhancing 
antibody production. Now, however, they are believed primarily to trigger an acute 
inflammatory reaction, thereby recruiting and activating antigen-presenting cells that 
capture the antigen. Additionally, adjuvants are believed to possibly help convert 
soluble antigens into a particulate form so that they are easily phagocytosed by 
antigen-presenting cells. The process of bridging innate and adaptive immunity also 
involves PMNs, a function elaborated in Box 1. 
 
 
Chronic inflammation and ‘frustrated resolution’. If resolution is a bridge between 
innate and adaptive immunity, chronic inflammation could be explained as reflecting 
incomplete resolution of the initial acute response that, in turn, does not fully engage 
an appropriate adaptive immune response. 
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This idea is supported by evidence that blocking the persistent type I interferon (IFN) 
response to lymphocytic choriomeningitis virus reduces innate immune activation, 
restores lymph node architecture and results in enhanced CD4+ T cell-mediated 
clearance of the virus12, 13. It emerges that whereas early, acute production of type 1 
IFNs promotes virus clearance, chronic exposure to these IFNs triggers 
immunosuppression via interleukin-10 (IL-10), programmed cell death ligand 1 
(PDL1) and indolamine signalling, and causes T cell apoptosis, collectively impairing 
the host’s ability to develop specific immunity14, 15. Similarly, chronic exposure to TNF 
attenuates T cell or adaptive immune responses. Repeated injection of TNF in mice 
dampens T cell responsiveness to recall antigens, whereas chronic anti-TNF therapy 
enhances T-cell reactivity16. Thus, whereas many early-phase Th-1-type cytokines 
drive inflammation, their persistence may paradoxically impair resolution, resulting in 
reduced antigen clearance and prevention of the development of adaptive immunity 
or long-term immune memory (Fig. 1b). Conceptually, many diseases driven by 
chronic inflammation may involve ongoing acute inflammation alongside frustrated 
attempts to develop adaptive immunity, with the latter ultimately turning maladaptive. 
(Fig. 1).  
 
 
 
 
Anti-inflammation versus pro-resolution. 
The idea that resolution processes cause not only the termination of inflammation 
but also assist the shift from innate to adaptive immunity affords additional 
opportunity to target diseases that involve inflammation or chronic inflammation — 
specifically, by promoting resolution. It has therefore been particularly important to 
dissociate the meaning of ‘anti-inflammation’ from that of ‘pro-resolution’1, 17. Many 
investigators confuse the two concepts by reporting on the use of, for example, 
prophylactic (that is, pre-initiating stimuli) pharmacological inhibition, targeted 
inhibition of factors expressed during early inflammatory onset, or the use of mice 
that over or underexpress genes that are implicated in both inflammation and 
resolution18-22. Targeting only resolution should involve modifying the course of an 
already established inflammation-driven disease, in a clinically relevant manner, by 
harnessing endogenous ‘off switches' (be they signalling cascades or cellular 
interactions) that cause inflammation to resolve (Fig. 2). 
 
Many effective anti-inflammatory treatment regimens are on the market (including 
NSAIDs, anti-cytokine therapies and steroids); however, switching off the underlying 
disease process is much more challenging. Hypothetically, diseases that are driven 
by ongoing inflammation could be treated by activating pro-resolution pathways that 
might be pathologically silenced and/or by agonising functional pro-resolution 
pathways. Indeed, combining pro-resolution with anti-inflammatory technology might 
transpire to be a superior strategy to existing approaches. However, there is 
circumstantial evidence from human studies that inflammation and resolution may 
not be mutually exclusive events. For instance, although macrophages are the 
principle drivers of synovial inflammation in patients with rheumatoid arthritis, the 
immediate decrease in the numbers of cells in the synovial fluid observed after 
beginning the anti-inflammatory TNF-specific antibody therapy was not due to 
apoptosis at the site of inflammation23. Given the steady infiltration of monocytes into 
the synovium in rheumatoid arthritis24, the rapid decrease in synovial macrophages 
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observed after antirheumatic treatment might result from an alteration in macrophage 
retention, rather than changes in monocyte influx. Thus, this disease might be 
sensitive to treatments targeting the synovial retention of inflammatory cells — in 
which case, simply inhibiting ongoing inflammation may promote resolution (see 
below). 
 
Hastening resolution was originally feared to lead to incomplete clearance of the 
original trigger, especially in the context of infections; however, specialised pro-
resolution mediators have now been shown not just to promote resolution processes, 
but also to augment cellular anti-microbial function, for instance increasing PMN and 
macrophage bacterial phagocytosis25. Thus, unlike anti-inflammatory approaches, 
approaches to augment pro-resolution pathways should not increase susceptibility to 
infection per se.  
 
 
Initiation of resolution 
Generally, conventional anti-inflammatory therapies are based upon the inhibition of 
factors that drive inflammation — that is, they antagonise pro-inflammation signals. 
Although this has afforded huge success in certain fields (such as rheumatoid 
arthritis and inflammatory bowel disease) there remains scope for improvement. 
Insights into resolution biology have afforded the possibility of harnessing factors that 
catabolise pro-inflammatory signalling; inhibiting pathways that break down pro-
resolution mediators; or selectively and potently activating receptors upon which pro-
resolution mediators act. The processes described below that lead to resolution and 
the factors that control them are not tied to any disease or tissue, but recount, in 
general terms, advances made in resolution biology. 
 
Removal of stimuli. For resolution to occur effectively the initiating injurious agents 
must be eliminated. This is particularly relevant for autoimmune diseases such as 
rheumatoid arthritis and systemic lupus erythematosus (SLE) that are driven by 
intractable endogenous antigens 26, 27. In the case of bacterial infection, the removal 
of the pathogen is facilitated in part by NADPH oxidase-mediated killing by PMNs28. 
Defects in the assembly of NADPH subunits, as occurs in the immunodeficient 
disorder chronic granulomatous disease and in tuberculosis, demonstrate the 
importance of antigen clearance for resolution29. 
 
Dampening pro-inflammatory signalling. Following stimulus removal, it is rational 
to suggest that the various families of receptors and their signalling pathways that 
triggered the release of pro-inflammatory mediators be turned off in order to prevent 
collateral damage from an ongoing pro-inflammatory state. Sepsis is a good example 
of when this does not occur: a cytokine storm may be witnessed despite negative 
bacterial blood cultures, suggesting exaggerated and persistent activation of the 
innate immune system despite removal of the stimulus. A number of regulatory 
mechanisms have evolved to keep the signalling factors that drive the innate 
immune system in check30.  
 
For example, the transmembrane molecule leucine rich repeat-containing protein 33 
(LRRC33) negatively regulates Toll-like receptor (TLR) signaling and subsequent 
nuclear factor-κB (NF-κB) activation, thus dampening TLR-driven pro-inflammatory 
events31. LRRC33 is functionally similar to RP105 (also known as CD180), an 
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endogenous inhibitor of TLR4 signaling., DCs lacking RP105 exhibit increased NF-
κB activation and pro-inflammatory signaling in response to lipopolysaccharide (LPS) 
challenge32. Separately, the multifunctional deubiquitinase cylindromatosis was 
recently shown to negatively regulate NF-κB signalling and to be an inducible 
negative-feedback regulator of bacteria-induced inflammation33. Additionally, the 
immune-suppressive lipid mediator prostaglandin E2 (PGE2)34 inhibits protein 
expression of TLR435. Taken together, mediators such as LRRC33, RP105, 
cylindromatosis and PGE2 typically ensure that inflammatory signalling is dampened 
after acute inflammatory responses. 
 
Post-transcriptional regulatory mechanisms — such as those that restrict the stability 
and/or translation of various mRNAs — have also evolved. Many of these mRNAs 
possess adenine- or uridine-rich elements (AREs) that recruit destabilizing factors 
and translational silencers to their 3′ untranslated regions (UTRs)36. ARE-binding 
proteins that destabilize these mRNAs include tristetraprolin (TTP), B-related factor 1 
(BRF1), BRF2, KH type-splicing regulatory protein (KSRP; also known as FUBP2), 
and AU-rich element RNA-binding protein 1 (AUF1). TTP interacts with AREs via its 
zinc finger and destabilizes mRNA transcripts that encode several inflammatory 
modulators, including granulocyte–macrophage colony-stimulating factor (GM-
CSF)37,CSF25, IL-238, IL-639, inducible nitric oxide synthase (iNOS)40, 
cyclooxygenase 2 (COX2)41, IFNγ 42 and TNF43. Transcription of TTP itself is also 
triggered in a feedback loop by inflammatory-like stimuli including TNF43, LPS44, and 
IFNγ39, in order to dampen the expression of inflammatory cytokines and promote 
resolution of inflammation43. By contrast, ARE-binding proteins that inhibit mRNA 
translation include T cell intracellular antigen 1 (TIA1), TIA receptor (TIAR), CUG 
triplet repeat RNA-binding protein 2 (CUGBP2; also known as CELF2) and fragile X-
related protein 1 (FXR1)45, 46. Targeted deletion of Tiar enhances the production of 
pro-inflammatory proteins in LPS-activated macrophages, and mice lacking TIA1 are 
more susceptible to LPS-induced septic shock than wild-type littermates, owing to 
overproduction of TNF47. The factors described here to regulate pro-inflammatory 
signalling at the mRNA level therefore represent alternative targets for the 
development of novel drugs to treat diseases driven by on-going or over exuberant 
inflammation. 
 
Steroid receptor co-activator 3 (SRC3) is a component of complexes that involve NF-
κB, peroxisome proliferator-activated receptor (PPAR) and glucocorticoid receptor 
transcription factor. Interestingly, SRC3 can either promote or inhibit inflammatory 
responses by regulating rates of mRNA transcription. Src3–/– mice are hypersensitive 
to LPS challenge because they overexpress pro-inflammatory cytokines such as 
TNF, IL-6 and IL-1β. Specifically, the translation of Tnf and Il1b transcripts is higher 
in macrophages lacking SRC3 than in wild-type controls. Indeed, SRC3 binds TIA1, 
leading to an increase in the binding of TIA1 to the ARE of Tnf mRNA, inhibiting its 
translation. Thus, SRC3 and TIA1 cooperatively repress the expression of reporter 
constructs that bear the TNF 3ʹ UTR. Together these findings show that SRC3 
functions as both a transcriptional co-activator and a translational co-repressor. This 
is an example of a regulatory protein that is involved in both the initiation and 
resolution phases of the inflammatory response, thereby representing a possible 
opportunity to increase or reduce inflammation as clinically appropriate. 
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IFNγ-treated macrophages provide another example of a temporally staggered 
negative-feedback inhibition of cell activation48. IFNγ induces the expression of the 
acute-phase response protein ceruloplasmin48, 49 as well as the assembly of the 
IFNγ-activated inhibitor of translation (GAIT) complex, which binds to the GAIT 
element. The GAIT element is a 29-nucleotide hairpin found in the 3ʹ UTRs of 
ceruloplasmin mRNA, which, in turn, targets components of the translation initiation 
machinery to inhibit protein synthesis50. As a result, after ceruloplasmin is secreted 
from IFNγ-activated macrophages in order to combat infection or injury, its synthesis 
is turned off. Transcripts encoding several other inflammatory mediators — including 
CCL22, CCR3, CCR4 and CCR6 — contain functional GAIT elements51, 52, 
suggesting the GAIT complex has an important influence on the magnitude and 
duration of inflammatory reactions.  
 
The transcription factor zinc finger CCCH domain-containing protein 12A (ZC3H12A) 
acts downstream of CCL2, and is another immunoregulatory zinc-finger protein that 
negatively regulates macrophage activation and TNF and iNOS production; it does 
this by inhibiting NF-κB53. Indeed, production of IL-6 and IL-12p40, but not of TNF, is 
increased in TLR-activated ZC3H12A-deficient macrophages owing to increased Il6 
and Il12p40 mRNA stability. In addition, ZC3H12A-deficient mice succumb to a 
chronic inflammatory condition that is characterized by increased levels of 
immunoglobulins and autoantibodies, increased lung-infiltrated leukocytes and 
hyperresponsive T cells and macrophages54.  
 
Several microRNAS (miRNAs) have emerged as key regulators of TLR pro-
inflammatory signalling pathways. For example, the NF-B-inducible miRNA miR-
146 inhibits translation of mRNA encoding IRAK1, IRAK2 and TRAF655. As IRAK1 
and TRAF6 are required for NF-κB activation, this function of miR-146 leads to a 
negative regulatory loop56. By corollary, overexpression of miR-146 results in a 
decrease in various chemokines and cytokines, including CXCL8, CCL556, IL-6, 
CXCL857, 58 and IL-1β59, and thereby prevents overinflammation, bringing the system 
back to homeostasis. As expected, mir-146a-knockout mice exhibit loss of 
immunological tolerance and their macrophages are hyperresponsive to LPS. 
Another miR, miR-21, is induced in macrophages via NF-κB and MyD88 upon LPS 
stimulation. miR-21 controls inflammation by downregulating the translation of the 
pro-inflammatory tumor suppressor programmed cell death 4 (PD4)60, an inhibitor of 
IL-10 production. As IL-10 blocks NF-κB, miR-21 represents another negative feed-
back regulator of LPS-driven inflammation, with potential in the resolution of 
inflammation.  
 
Elucidating the role of negative feedback regulators of inflammation is an attractive 
strategy. Indeed, miRNAs are increasingly popular drug targets. Proteins that are 
considered difficult to modulate pharmacologically can now be targeted via their 
miRNA gene regulators, enabling the treatment of currently seemingly untractable 
diseases. Targeting miRNAs requires innovation at the level of drug discovery; this is 
well described elsewhere (see Ref. 61).  
 
However, not all miRNAs or ARE-binding proteins dampen pro-inflammatory 
signalling pathways. For example, miR-15562, 54 enhances the expression of TNF in 
macrophages and ZCCHC11 stabilises mRNA that encodes IL-664. Nonetheless, 
defects in one or more ARE-binding proteins and/or miRNAs could explain the 
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aetiology of some ongoing inflammation-driven diseases, such as sepsis. Although 
there is more study of anti-inflammatory signalling pathways (such as cyclic AMP, IL-
10 and transforming growth factor-β1 (TGFβ1)) than of the negative regulation of 
pro-inflammatory signalling pathways, the latter nonetheless represents a critically 
important aspect of biology and medicine. Moreover, this area of research provides 
an opportunity to pharmacologically manipulate their function in order to switch off 
persistent inflammation at its source. 
 
Clearance of pro-inflammatory mediators. Following disposal of the injurious 
agent and turning off signalling pathways, the levels of cytokines, chemokines, 
eicosanoids, cell adhesion molecules and other inflammatory mediators must revert 
back to their pre-inflamed state.  
 
One example of a type of pro-inflammatory mediator that is catabolised during 
resolution is the prostaglandins, which are involved in vasodilation, oedema 
formation and allodynia (reviewed in detail in Ref. 65). Prostaglandins first undergo 
oxidation of the 15(S)-hydroxyl group by a 15-hydroxyprostaglandin dehydrogenase 
(which metabolizes E-series prostaglandins, lipoxins, 15-HETE and 5,15-diHETE to 
their corresponding 15-keto compounds). Second, an NADPH- or NADH-dependent 
Δ13-15-ketoprostaglandin reductase reduces the Δ13 double bond. Further 
catabolism of prostaglandins, some HETES and lipoxins occurs via the beta-
oxidation pathway, which is common to fatty acids in general. Specifically, the 
carboxyl end of the molecule is catabolised to form short-chain metabolites that are 
excreted in the urine. Some of the eicosanoids are also excreted following 
glucuronidation. 5-HETE and leukotrienes (LTs) undergo beta-oxidation from the 
omega-terminus following an initial omega-hydroxylation. Disruption of these 
pathways is known to contribute to disease states (for example, sepsis) and targeted 
augmentation may be expected to reverse pathological alterations66. 
 
Atypical chemokine receptors such as D6 bind ligands without initiating classical 
signalling pathways, thereby acting as a type of scavenging system for pro-
inflammatory signals. D6-deficient mice produce an excess of chemokines in 
response to 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced skin inflammation, 
resulting in a notable inflammatory pathology with similarities to human psoriasis (for 
review see Ref. 67). In addition, the chemokines CCL3 and CCL5 are increased in 
peritoneal exudates of Ccr5–/– mice during the resolution of acute peritonitis, but in 
these animals are scavenged by apoptotic PMNs in a CCR5-dependent manner. 
CCR5 expression on the surface of apoptotic PMNs was reduced by pro-
inflammatory cytokines and increased by pharmacological application of pro-
resolution lipid mediators such as lipoxin A468. Thus, there are endogenous systems 
that can facilitate the clearance of pro-inflammatory mediators and that, when 
dysregulated, may lead to chronic inflammation. Conversely, pro-inflammatory 
catabolic pathways could be harnessed therapeutically to drive ongoing inflammation 
towards resolution.  
 
Resolution 
Cell death and the clearance of effete leukocytes is an area of resolution biology that 
has been studied in much detail and, as a consequence, has the potential to provide 
numerous targets for pro-resolution drug development. Here, we discuss the many 
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fates of cells during resolution, with a focus on the local death of PMNs and their 
efferocytosis by mononuclear cells.  
 
Leukocyte death. Inflammatory cells can be eliminated in one of three ways: 
through retro-transendothelial migration back into systemic circulation; through 
lymphatic drainage (to enable subsequent participation in adaptive immune 
responses); or through cell death in the inflamed tissue. Local cell death occurs in 
many ways, including autophagy, excitotoxicity, pyroptosis, necrosis, necroptosis, 
NET-osis and caspase-mediated apoptosis69, 70 (Box 2). The predominant 
mechanism of cell death in a given disease state is not without reason or 
consequence: instead it plays an active part in determining the outcome of 
inflammation.  
 
Granulocyte death by apoptosis during resolution has been extensively studied (see 
below). Key molecules and pathways involved in maintenance of leukocyte survival 
or apoptotic death include NF-κB, phosphoinositide 3-kinase (PI3K), myeloid 
leukemia cell differentiation protein 1 (MCL1) and cAMP. Regulated clearance of 
apoptotic cells leads to shutdown of immune cellular activity (in particular 
efferocytosing macrophages) and the consequent inhibition of inflammatory 
responses. Therefore, it is considered that granulocyte apoptosis followed by 
phagocytosis (efferocytosis) is the most ‘desirable’ form of cell death for successful 
resolution71. 
 
Granulocytes survive in the circulation for only a few hours, but various soluble 
mediators released at sites of inflammation can influence the survival of diverse 
granulocyte subtypes. For example, PMN longevity is extended by IL-6, IL-8, GM-
CSF and bacterial products, whereas eosinophil survival is augmented by cytokines 
such as IL-3, IL-5 and GM-CSF72. These survival factors, in turn, activate several 
signalling pathways including the cyclin-dependent-kinase (CDK), NF-κB, PI3K–Akt, 
cAMP and mitogen-activated protein kinase (MAPK) pathways73. Generally, these 
signalling pathways lead to enhanced levels of pro-survival molecules and 
diminished levels of pro-apoptotic molecules. NF-κB, in particular, alters the 
expression of many intracellular pro-survival proteins, including BCL-2 family 
members (such as BCL-xL and XIAP). Therefore, pharmacological inhibition of NF-
κB and IKKα influences granulocyte survival and apoptosis and consequently drives 
inflammatory resolution74.  
 
In addition to NF-κB, the intracellular pro-apoptotic protein BAD (BCL-2-associated 
death promoter) is an important downstream target of PI3K–AKT. AKT 
phosphorylates BAD, thereby suppressing apoptosis and promoting cell survival75. In 
myelin oligodendrocyte glycoprotein-induced experimental autoimmune 
encephalomyelitis (a model of multiple sclerosis), PI3Kγ-deficient mice developed 
milder clinical disease and decreased levels of CCL2 and CCL5 in brain tissue 
compared with wild-type controls, concomitant with increased leukocyte apoptosis in 
the PI3Kγ-deficient animals76. Importantly, neither PI3Kγ-deficiency nor the PI3K 
inhibitor AS-605240 affected the magnitude of the acute onset phase of the disease, 
indicating that in this model, PI3Kγ may have a role in promoting leukocyte survival 
— preventing resolution and extending inflammation. 
 
11 
 
The role of cAMP in apoptosis is complex as in some cells types is drives 
programmed cells death, while others it prevents it77. For instance, in vitro cAMP 
inhibits granulocyte apoptosis and the subsequent recognition and uptake of 
apoptotic cells by macrophages78, 79. However, increasing cAMP function in vivo in 
LPS-induced pleurisy (with the phosphodiesterase 4 inhibitor rolipram, the adenylate 
cyclase activator forskolin or the cAMP analogue db-cAMP) 4 hours after LPS 
challenge dose-dependently prevented PMN accumulation but, in contrast to in vitro 
studies, promoted PMN apoptosis80. Independent of its effects on phagocytosis of 
apoptotic cells, rolipram causes a direct, cAMP-dependent switch of M1-like pro-
inflammatory macrophages to resemble those found during resolving inflammation81. 
Collectively, these findings show that cAMP signalling regulates processes that limit 
tissue injury, and that modulation of cAMP levels represents a central therapeutic 
strategy in the control of resolution. However, this will most likely be context, tissue 
and stage of inflammation dependent.  
 
All MAPK subtypes (namely, extracellular-signal-regulated kinase 1 (ERK1) and 
ERK2, c-Jun amino-terminal kinases (JNKs) and p38 MAPK) play a part in 
modulating granulocyte apoptosis. However, their respective roles in cell survival are 
cell-type- and context-specific82. ERK is typically associated with the regulation of 
activation and survival of various cell types, including granulocytes83. In 
carrageenan-induced pleurisy, for instance, the ERK1 and ERK2 inhibitor PD98059 
hastens resolution of inflammation, with fewer PMNs and macrophages in the pleural 
cavity and increased PMN apoptosis84. By contrast, the exact role of p38 in the 
control of granulocytes survival is controversial; this pathways has been described to 
have both pro-apoptotic85 and anti-apoptotic86 effects. During resolution, the 
restriction of p38 MAPK activation by MAPK phosphatase 1 controls the pro- to anti-
inflammatory macrophage polarization switch during muscle healing87. Further, 
during the non-phlogistic phagocytosis of apoptotic cells, the p38 signalling pathway 
leads to the activation of certain transcription factors that reprogramme the 
macrophage phenotype from pro- to anti-inflammatory, resulting in release of IL-1088.   
 
A role for CDK in granulocyte survival and in delaying resolution in experimental 
animal models was illustrated with the use of the CDK inhibitor roscovitine, which 
inhibits the ability of CDK7 and CDK9 to phosphorylate RNA polymerase II89. This 
compound caused apoptosis of GM-CSF-, LPS- or glucocorticoid-stimulated human 
PMNs90, 91. Additionally, roscovitine and AT7519 (a CDK inhibitor in clinical trials for 
treatment of cancers, neurodegenerative diseases, viral infections and 
glomerulonephritis) dose-dependently induced apoptosis of human eosinophils92.  
Importantly, in vivo, roscovitine enhanced the resolution of established PMN-
dependent inflammation in models such as carrageenan-induced pleurisy, 
carrageenan-induced arthritis and bleomycin-induced lung injury90. Moreover, in a 
murine model of ovalbumin-induced allergic pleurisy, AT7519 triggered eosinophil 
apoptosis and subsequent phagocytic clearance92. These data highlight the 
importance of phagocytic clearance of inflammatory cells to the resolution process. 
 
Collectively, targeting death pathways of pathogenic cells that persist at sites of 
chronic inflammation has its virtues. The effectiveness of this approach will depend 
on being able to selectively target cells of interest, such as PMNs, eosinophils or 
Th1-type lymphocytes, at the right site, while leaving pro-resolving, pro-homeostatic 
and bystander cells intact.  
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Clearance of dead cells. Defective clearance of apoptotic bodies has been linked 
with autoimmunity93 and other chronic inflammatory diseases94; as a result, 
efferocytosis has been considered a key requirement for inflammatory resolution and 
for the preservation of immune tolerance71. When a PMN nears the end of its life it 
releases chemoattractants, including nucleotides95, lysophosphatidylcholine96 and 
sphingosine-1-phosphate97, that signal its whereabouts to mononuclear phagocytes. 
In addition, endothelial monocyte-activating polypeptide II98, ribosomal protein S1999 
and thrombospondin 1100 direct mononuclear phagocytes towards apoptotic cells. 
Interestingly, it has been suggested that apoptotic cells also release resolvin E1 
(RvE1) and protectin D1101, lactoferrin and annexin A1, which inhibit further 
recruitment of granulocytes but not of mononuclear phagocytes. This selectivity may 
contribute towards the predominance of mononuclear cells that mediate resolution 
and optimal wound healing102.  
 
During apoptosis, the dying cell loses expression of repellant ‘don’t-eat me’ cell-
surface molecules such as CD31103 and CD47104, and upregulates expression of 
various ‘eat-me’ signals, including phospholipids, nucleotides and phosphatidylserine 
(PS), which undergo externalization105. The interaction between tissue-resident 
macrophages and these ‘eat-me’ signals105-109 ensures that apoptotic cells are 
efficiently removed from tissue prior to membrane rupture and the release of 
histotoxic mediators that would theoretically damage and perpetuate the 
inflammatory response.  
 
Importantly, uptake of apoptotic cells trigger the conversion of phagocytosing 
macrophages to an immune-regulatory or pro-resolution phenotype81, 110, limiting 
their propensity for tissue damage and maintaining immune tolerance both locally 
and in draining lymphoid organs4, 111-113. This phenotype is characterized by 
upregulated expression of co-inhibitory molecules such as PDL1 and ICOS ligand; 
the release of the anti-inflammatory cytokines IL-10 and TGFβ; the secretion of 
PCNA-associated factor, PGE2 and cAMP81, 114-116; and the inhibition of the release 
of pro-inflammatory cytokines including TNF, GM-CSF, IL-12, IL-1β and IL-1825, 59-61. 
Macrophages that have ingested apoptotic cells also release pro-resolving lipid 
mediators such as RvE1, protectin D1 and maresins101 117, contributing to 
termination of the inflammatory process. 
 
There are hypothetical benefits in therapeutically triggering apoptosis accelerate 
resolution, but this must be accompanied by robust efferocytosis, as apoptotic cells 
and their associated auto-antigens potentially underlie disease progression in SLE93. 
Moreover, as discussed below, efferocytosis is an immunosuppressive process and 
so opens a window of potential infectious opportunity118. Therefore, a better 
understanding of the interaction between apoptotic cells and phagocytosis, and the 
soluble mediators that modulate this process will be important in understanding both 
the pathogenesis of chronic diseases and delineating novel ways of treating them.  
 
 
Macrophage phenotypes during resolution  
Early studies on acute inflammation suggested that PMN clearance and the 
restoration of tissue homeostasis represented the end of successful resolution2, 17. 
However, as described above, we recently reported on a third phase of inflammation, 
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which we called ‘post-resolution’, in a murine model of zymosan-induced peritonitis, 
suggesting that the classic view of resolution needed to be expanded4.  
 
This phase persisted for weeks and involved populations of Ly6chi MDSCs, DCs and 
macrophages. These monocyte-derived cells amplified the ensuing adaptive immune 
response and maintained immune tolerance by generating inducible regulatory T 
cells4. We4 and others10 also found that Ly6chi MDMs remained in tissues for months 
after inflammation had resolved, and that these cells had a role in dictating the 
magnitude and duration of subsequent acute innate inflammatory stimulation 
(remniscent of studies of polysensitization). In another study in mice, DCs were 
found not to return to their steady-state phenotype after resolution of Th2-mediated 
inflammation, but instead persistently expressed high levels of co-stimulatory 
molecules, such as CD80, CD86, and intercellular adhesion molecule 1 (ICAM1), 
and the Th2-skewing molecules OX40 ligand and Ym1/2 lectin. This enhanced 
maturation status of airway DCs facilitated neosensitization up to at least 1 month 
after inflammation119. These findings emphasize that once inflammation has 
resolved, there is a hitherto unappreciated phase of ‘adapted homeostasis’, in which 
cells of the monocyte–macrophage lineage play a central part in modulating 
subsequent responses to infection or allergens.  
 
Therefore, despite experiencing the same inflammatory cues, monocyte or 
macrophage populations might come to possess diverse phenotypes that are neither 
M1 (pro-inflammatory) nor M2 (anti-inflammatory), but commensurate with the phase 
of inflammation. Indeed, this notion probably extends to macrophage populations in 
tissue niches under different physiological and disease conditions120, 121. For 
instance, during the maximal fibrotic stage of liver fibrosis elicited by carbon 
tetrachloride, Ly6chi monocytes give rise to MDMs122. These macrophages are a 
hybrid of the conventional M1- and M2-like cell phenotypes and express elevated 
levels of growth factors and tissue remodelling-related factors needed to clear fibrotic 
plaques, and exhibit elevated ERK signalling. Interestingly, using liposomes to 
elevate ERK signalling enhanced anti-fibrotic macrophage phagocytosis in vivo and 
found that pharmacologically elevating the phagocytic nature of their anti-fibrotic 
macrophage using liposomes accelerated the resolution of liver fibrosis. 
 
Data from these reports support the idea of macrophage plasticity — that the 
macrophage phenotypes that either drive or resolve diseases will be tissue-, 
stimulus- and phase-specific. Indeed, diverse populations of macrophage 
phenotypes have been reported in various experimental models of renal (that is, 
single-organ) inflammation (for review see123). The precise nature of macrophage 
phenotypes involved in each disease will depend on which disease mechanism 
predominates in a given organ. Whereas infection and cell necrosis trigger the 
generation of pro-inflammatory or M1-like macrophages that exacerbate renal cell 
damage, apoptotic cells induce anti-inflammatory, immune-suppressive 
macrophages that promote epithelial and vascular repair. Indeed, vascular and 
epithelial healing that is insufficient despite abundant growth factor secretion will 
promote profibrotic ‘M2a’ or ‘wound-healing’ macrophages that accelerate 
fibrogenesis. In a separate example, inflammatory monocytes recruited to sites of 
skeletal muscle injury switched into anti-inflammatory macrophages to support 
myogenesis124 in a manner dependent on AMPKα1125, a master regulator of energy 
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homeostasis. Thus, like the peritoneum4, a single organ like the kidney, or tissue 
such as skeletal muscle, can generate diverse populations of immune cells 
depending on disease aetiology.  
These data indicate that there are many diverse routes to resolution; thus, it is 
unlikely that one single therapeutic intervention will be a panacea for all chronic 
inflammatory diseases. Instead, it will be increasingly imperative to focus on a 
specific pathology, appreciating both the heterogeneity within classical clinical 
diagnoses and the factors that influence the inflammatory phenotype, to successfully 
admin targeted pro-resolution therapy is to be.  
  
Targeting pro-resolution pathways 
The aspects of the pro-resolution cascade described above can be targeted in order 
to alter the inflammatory profile, without compromising tolerance. Modulating any of 
these events, along with supplementation of, or inhibition of the catabolism of, 
soluble pro-resolution factors to extend their pharmacological half-life, represent 
tractable drug targets to invoke resolution. Table 1 describes most of the currently 
known mediators, receptors and mechanisms that exert pro-resolution actions. 
 
The number, intricacy and applications of human inflammatory models are 
increasing (Box 3), but zebrafish and mice (Box 4) have provided us with the 
quantifiable resolution indices we use in these models. These indices include the 
maximum cell number present at the peak of the inflammatory response (ΨMAX), the 
time at which ΨMAX occurs (TMAX), and the time at which cell numbers are reduced by 
50% of ΨMAX (T50). The resolution interval (Ri) is the time taken for cells at ΨMAX to 
reach T50 (that is, to be reduced by 50%)126. These metrics allow comparative 
efficacy study of existing and novel pro-resolution therapies. 
 
In terms of modulating cell recruitment to sites of infection or injury, and as 
mentioned above, it is important to differentiate between (anti-inflammatory) factors 
that only inhibit granulocyte trafficking into tissues (such as metformin127) versus 
those that that are also pro-resolution. For instance, lipoxins and resolvins (Rvs) 
inhibit PMN trafficking and enhance efferocytosis of apoptotic cells, without 
compromising host defence128, and RvD1, RvD5 and protectin D1 accelerate 
leukocyte bacterial killing and enhance antibiotic efficacy25.  
 
There are several strategies for enhancing PMN apoptosis in vivo — including CDK 
inhibition (using roscovitine or AT7519), or inhibition of PI3K, ERK1, ERK2, or NF-κB 
(using the PGD2 metabolite 15-deoxyΔ12-14-PGJ2)129. However, for maximum benefit, 
this must be accompanied by efferocytosis by macrophages. This can be augmented 
by melanocortins, glucocorticoids, annexin A1 and its mimetic Ac2-26 as well as lipid 
mediators130. Recently, Bcl2-overexpressing mice showed impaired PMN apoptosis 
in a model of pneumococcal meningitis, and this effect was accompanied by high 
levels of IL-1β and granulocyte-CSF, and reduced levels of anti-inflammatory TGFβ, 
resulting in persistence and prolonged activity of PMNs and thus more-severe 
disease131. Inducing PMN apoptosis using the CDK inhibitor roscovitine improved 
thereduced brain tissue damage and accelerates recovery following pneumococcal 
meningitis. 
.  
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Although hastened PMN apoptosis and the resultant re-programming of 
macrophages towards an immune-modulatory or pro-resolution phenotype may be 
beneficial, resolving inflammation before the tissue is fully immunologically restored 
may open a window of ‘infectious opportunity’. The lung, for instance, is highly 
susceptible to secondary bacterial infections as a consequence of injury. Apoptotic 
cells suppress in vitro phagocytosis and killing of bacteria by alveolar macrophages 
in a PGE2-, prostaglandin EP2 receptor (PTGER2)- and cAMP-mediated manner118. 
Intrapulmonary administration of apoptotic thymocytes impaired lung recruitment of 
PMNs as well as clearance of Streptococcus pneumonia, again through a PGE2- and 
PTGER2-dependent pathway. These results suggest that, in addition to their 
beneficial homeostatic influence, pro-resolution programmes, at least in the lung, 
may dampen innate antimicrobial responses, leaving the host susceptible to 
secondary infection and perhaps necessitate the concomitant use of immune-
restorative agents such as PTGER2 antagonists to counteract these effects34. 
Moreover, the contrast between these findings from different infected sites 
(meninges and lung) re-emphasizes that the impact of various pro-resolution 
pathways on tissue integrity, repair and susceptibility to infection are most likely 
disease- and tissue-specific.  
 
Lipid mediators such as PGJ2 and RvD1 exert multiple levels of control on the 
inflammatory response, and mimetics based on their mode of action through g 
protein-coupled receptors (GPCRs) represent a tractable and very effective target for 
treating ongoing inflammation132. PGJ2 was one of the first COX-derived lipid 
mediators implicated as eliciting the resolution of innate-immune133 as well as 
regulating adaptive-immune inflammatory responses134-136. It is an agonist of the 
GPCR PPARγ, and represses the transcription of mRNAs encoding pro-
inflammatory mediators, inhibits protein translation137 and inhibits NF-κB-mediated 
transcription of pro-inflammatory genes138. PGJ2-mediated translational repression 
triggers a stress response, resulting in the assembly of stress granules139, 140 that 
reprogramme gene expression to allow cells to survive noxious stimuli. 
Complimentarily, RvD1 upregulates miR-146 to control NF-κB expression141. RvD1 
also upregulates miR-219 and miR-208a (the latter of which triggers IL-10 
expression) in exudate cells isolated from the GPCR N-formyl peptide receptor 2 
(FPR2; also known as ALX)-overexpressing transgenic mice bearing a zymosan-
induced peritonitis. In Fpr2 knockouts, RvD1 had no effect on leukocyte infiltration, 
did not regulate miR-208a, and had no subsequent effect on IL-10 expression142, 
suggesting the actions of RvD1 are dependent on FPR2. Targeted, stratified 
application of either of these agents, either locally or systemically, could thus 
potentially help drive resolution in inflamed tissues.  
 
It must be emphasised that the targets discussed above are involved in pathways 
pertinent to acute, self-resolving inflammation. Whereas it is relatively easy to make 
already-resolving experimental inflammation resolve even faster, it is far more 
challenging, though more clinically relevant, to achieve this in diseases of different 
aetiology, chronicity and complexity. Granulomatous experimental autoimmune 
thyroiditis (G-EAT) is a T cell-mediated autoimmune disease that can be induced in 
genetically susceptible strains of mice by immunization with mouse thyroglobulin and 
adjuvant143. It is characterized by proliferation of thyroid epithelial cells, granuloma 
formation and infiltration of T lymphocytes, macrophages, multinucleated giant cells 
and PMNs. Neutralizing the endogenous pro-apoptotic molecule TNF-related 
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apoptosis-inducing ligand (TRAIL) in this model has little effect on the development 
of the lesion, but markedly inhibited lesion resolution144, 145. In mice that received a 
TRAIL-specific antibody, the inhibition of resolution correlated with the expression of 
TRAIL and of the anti-apoptotic molecules FLICE-like inhibitory protein (FLIP) and 
BCL-XL on thyroid inflammatory cells. These results suggest that endogenous 
TRAIL is not required for G-EAT initiation and development but is crucial for G-EAT 
resolution. Furthermore, TRAIL accelerated PMN apoptosis and resolution in LPS-
mediated acute lung injury and in zymosan-induced peritonitis146. Therefore, TRAIL 
may promote resolution of chronic inflammatory disease process, at least in part 
through altering the expression pattern of pro- and anti-apoptotic molecules of both 
tissue stromal and inflammatory cells. The example of TRAIL emphasizes that the 
resolution of complex chronic diseases (as well as of acute inflammation) is 
therapeutically achievable. 
 
Whereas the targets discussed here and elsewhere were empirically found to 
promote resolution, there are other drugs that exert striking anti-inflammatory as well 
as pro-resolution effects. Specifically, H2S has the anti-inflammatory effects of 
inhibiting granulocyte adhesion to, and transmigration across, the microvascular 
endothelium, and inhibiting myeloperoxidase activity, but also helps resolve 
inflammation by promoting the apoptosis of PMNs, the uptake of bacteria by 
phagocytes and the acquisition of an M2-like phenotype by macrophages147, while 
promoting tissue repair and restoration of tissue function148. Some of the pro-
resolution properties of H2S arise from its ability to selectively induce expression and 
activity of inducible COX, which produces pro-resolution lipid mediators. Inhibition of 
H2S synthesis in the gut, for example, leads to reduced COX expression, an 
increase in mucosal inflammation and impaired healing of experimentally damaged 
tissue — effects that may be rescued by H2S donors. As a consequence, several 
groups began to try to develop novel therapeutics that release H2S149. ATB-429 from 
Antibe Therapeutics is a derivative of mesalamine that releases H2S. ATB-249 
exhibits markedly enhanced anti-inflammatory, pro-resolution and pro-healing effects 
in rodent models of colitis compared with mesalamine, whereas the H2S-releasing 
NSAID ATB-346 (which is in Phase I for osteoarthritis), accelerates gastrointestinal 
wound repair, in stark contrast to its parental compound, naproxen, which causes 
gastrointestinal lesions149. Such agents clearly demonstrate the potential of the 
incipient class of pro-resolving therapies. 
 
 
Future strategies to target resolution 
Many advances have been made in understanding resolution and its constituent 
processes; now, we must learn how to control them with convincing efficacy. For 
example, a range of factors have a role in inflammatory resolution, including lipids 
(such as lipoxins, Rvs, protectins, maresins and PGD2 or cyclopentenone PGs), 
proteins (such as annexin A1 and secretory leukocyte protease inhibitor), proteins 
(such as annexin-, melanocortin- and chemerin-derived peptides), gaseous 
mediators (such as H2S and carbon monoxide (CO)), purines (such as adenosine) 
as well as the vagal nerve release of acetylcholine into the affected tissue. The 
question of where, when and how to therapeutically employ or manipulate these 
moieties remains. 
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Existing anti-inflammatories also possess pro-resolution properties: low-dose aspirin, 
triggers the production of epimeric forms of lipoxins (15 epi-lipoxin A4/B4), and 
glucocorticoids enhance efferocytosis. However, such drugs have unwanted side 
effects. It now clear though that a better understanding of their pharmacological 
mechanisms of pro-resolving action may be able to obviate these. For example, 
recent insights into melanocortin receptors have reinvigorated interest in the use of 
adrenocorticotophic hormone (ACTH) as a drug. ACTH not only induces cortisol 
production, but also exerts anti-inflammatory actions by: targeting melanocortin 
receptors present on immune cells; inhibiting granulocyte trafficking; suppressing 
cytokine synthesis; and driving macrophages towards an M2-like phenotype. These 
findings suggest that new ACTH-like melanocortin receptor-targeting drugs devoid of 
steroidogenic actions could possess potent pro-resolution effects150. Equally, forms 
of lipoxins that are endogenously produced following exposure to aspirin (known as 
aspirin-triggered lipoxins (ATLs) or long-lived mimetics of these may afford similar 
benefits to aspirin without the gastrointestinal and haemorrhagic sequelae. 
 
Theoretically, pro-resolution therapies may be superior to standard anti-
inflammatories, in that as well as suppressing the first four cardinal signs of 
inflammation, they may also affect tissue healing and function. Early evidence comes 
from murine studies of inflammation-induced bone loss. Pro-inflammatory cytokines 
such as TNF and IL-1 promote pathologic osteoclast resorption of bone and 
suppress the ability of osteoblasts to counteract bone erosion; however, during the 
resolution phase of the mouse K/BxN serum-induced inflammatory arthritis model, 
bone resorption ceased and appositional osteoblast-mediated bone formation was 
induced151. Remarkably, this resulted in repair of eroded bone — probably as a 
result of downregulation of the Wnt antagonists secreted frizzled-related protein 1 
(sFRP1) and sFRP2, and concomitant induction of the anabolic and pro–matrix 
mineralization factors Wnt10. 
 
Finally, and potentially most importantly, the translation of pro-resolution strategies to 
man is underway. The findings that membrane anti-inflammatory GPCRs including 
ChemR23, GPR32 and FPR2 transduce the pro-resolving effects of chemerin 
peptides, RvE1 and RvD1 (and that RvD2 exerts its effects through GPR18152) are 
not only novel and exciting developments in receptor biology, but may represent an 
important opportunity for pro-resolution drug discovery. A better understanding of 
these receptors, especially in chronic inflammatory settings, could guide novel drug 
discovery programmes aimed at using the fundamental actions of these effectors of 
resolution. This process has already started with a stable isopropyl ester analogue of 
RvE1, RX-10045 (Resolvyx Pharmaceuticals), which is being tested for its ability to 
resolve dry eye inflammation (Clinicaltrials.gov identifier: NCT00799552). 
 
Conclusion and future directions 
The development and application of pro-resolution therapeutic strategies to chronic 
inflammatory pathology may come to revolutionize the management of some of the 
oldest and most prevalent human ailments. By approaching such diverse disease 
states from the opposite perspective – asking not how to suppress the initiation and 
propagation of inflammation, but how to augment clearance of the triggering stimuli 
and resolve the host response to it – we will hopefully gain new insights into both the 
origin of chronic inflammation and pharmaceutical means of addressing it. 
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This article has described compelling evidence that modification of the pathways that 
initiate pro-resolution processes (removal of the stimuli, dampening of pro-
inflammatory signalling and enhanced mediator catabolism) and these key events 
themselves — apoptosis of infiltrating inflammatory leukocytes, the clearance of 
these cells, and associated alterations in macrophage phenotype — can improve the 
outcome of disease in animal models. Although the medicinal means of directing and 
orchestrating these fundamental processes are currently in their infancy, the 
potential reward from harnessing pro-resolution pathways is too great to ignore.  
 
Various promising strategies have been elucidated; nevertheless, there is a pressing 
need to develop appropriate human models of resolution in which their efficacy can 
be validated. Given the heterogeneity of inflammatory disease and the challenges 
posed by co-morbidity, polypharmacy and demographic variance in the clinical 
population, it is implausible that one ‘pro-resolution drug’ will be a panacea. Instead, 
the thoughtful development of a stratified approach in targeted patient groups, 
accounting for tissue-site differences in resolution pathways and disease-specific 
factors, is most likely to bear fruit. 
 
 
Box 1 | The role of PMNs in resolution and adaptive immunity  
Notwithstanding the undoubted function of PMNs in killing infection, there is a 
presupposition that PMNs are ‘bad’ in self-resolving inflammation — the context in 
which pro-apoptotic or pro-efferocytosis drugs have been tested. Previously, we 
made a link between the classic model of acute inflammatory resolution and the 
establishment of adaptive immunity. Others have also made important observations 
that indicate a hitherto unappreciated role for PMNs in this process, including that of 
‘lymph node cell shutdown’.  
 
The term lymph node cell shutdown describes how — unlike in the steady state, 
when the rate of lymph flow and the output of cells in the efferent lymph is constant 
— there is a transitory decrease of lymphocytes exiting the efferent lymph within 
hours of antigen or adjuvant injection153-155. Lymph node shutdown is thought to 
facilitate the development of adaptive immunity. Lipid mediators including PGE2 and 
thronboxane A2 are thought to be the critical component in this process154, 156.  
 
A later study showed that within minutes of infection or vaccination, PMNs transit to 
regional draining lymph nodes and suppress ensuing CD4 and B cell responses in a 
thromboxane-mediated process157. While its belived that PMN prostanoids directly 
inhibit T cell and B cell responses by inhibiting their proliferation; recent studies 
suggest that PGE2, for instance drives CD4 Th1 immune cells resposnes158. In 
addition, PMNs compete with DCs for antigen, limiting antigen availability to DCs; 
such competition may further compromise the quality of adaptive immune responses.  
 
Thus, while we appreciate the established role PMNs have as first-line defenders 
against pathogens, these cells also play an important part in modulating adaptive 
immune responses. Whether these effects are beneficial to the host depends on the 
nature of the inflammatory stimulus — infection or vaccination. However, what is 
clear is the need to understand the broader role PMNs have during acute 
inflammation, and the impact that hastening PMN apoptosis may have on the nature 
and magnitude of the ensuing adaptive immune response. Moreover, the role of 
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PMNs in modulating T cell or B cell responses in chronic inflammation that is driven 
by maladaptive immunity warrants further investigation. It is for this reason that we 
need to develop more-reflective models of chronic inflammation, to establish the 
overall virtues and limitations associated with hastening PMN apoptosis, as the role 
of granulocytes in chronic, maladaptive immunity may not be the same as in acute 
inflammation. 
 
Box 2 | Alternative forms of cell death in inflammation 
Besides apoptosis, there are several alternative forms of cell death that can occur 
following inflammation, including autophagy, neutrophil extracellular trap (NET)-osis 
and necrosis.  
 
Autophagy is the ordered degradation and recycling of unnecessary or dysfunctional 
intracellular components. Autophagic cell death occurs after nutrient deprivation or 
growth factor withdrawal or in response to rapamycin or inflammatory-like stimuli 
such as TLR agonists, phorbol myristate acetate (PMA) or reactive oxygen species. 
It typically occurs without chromatin condensation and is accompanied by cytoplasm 
vacuolization159. Autophagy provides a mechanism for the elimination of intracellular 
microorganisms. It also controls inflammation — through regulatory interactions with 
innate immune signalling pathways, by removing endogenous inflammasome 
agonists and through effects on the secretion of immune mediators160.  
 
In addition to autophagy, PMN extracellular traps, or NETs, that are composed of 
DNA and granule constituents lead to non-apoptotic cell death termed NETosis161. 
Although NETs are designed to kill bacteria and fungi, they are proposed to worsen 
inflammation. Consistent with this, PMNs isolated from synovial fluid or peripheral 
blood of patients with acute gout — an inflammatory condition associated with the 
accumulation of uric acid in synovial joints — produce NETs162.  
 
Cells may also undergo necrosis in response to signalling via TNF family death 
receptors, pathogen sensors, antigen-specific T cell receptors and genotoxic stress. 
Necrosis can occur either as a primary event (in which case, it is known as primary 
necrosis) or secondary to apoptosis, if apoptotic bodies are not immediately cleared 
(as in the presence of pathogen-encoded caspase inhibitors)163. Necrosis was 
traditionally viewed as an uncontrolled mode of cell death until it was found that 
certain types of necrosis are tightly regulated by signal transduction pathway. In 
particular, the protein serine-threonine kinase receptor interacting protein 1 (RIP1) 
family member RIP3 is now considered a key mediator in caspase-independent cell 
death163, 164, which is now known as necroptosis or programmed necrosis. Some 
pathogens in monocyte-macrophages, PMNs and eosinophils can disrupt death 
pathways as a survival strategy, impairing antimicrobial functions of immune cells165, 
166.  
 
Although necrosis has been traditionally associated with enhanced inflammation and 
tissue injury and therefore considered to be ‘unwanted’167, it has been suggested 
that necrotic cell death can inhibit inflammatory reactions168. For example, annexin 
A1, a glucocorticoid-inducible anti-inflammatory and pro-efferocytotic protein, is 
externalized on granulocytes during secondary necrosis. Here, it acts as an immune-
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dampening system, counteracting inflammatory responses when apoptotic cells are 
not cleared169.  
 
The relative virtues of necrotic cell death on inflammation are beyond the scope of 
this Review, but these findings muddy the waters in terms of what was once thought 
to be good cell death (apoptosis) versus bad death (necrosis). Indeed, while 
autophagic-like PMNs have been reported in rheumatoid arthritis, septic shock and 
cystic fibrosis170, 171, a recent study on the inflammatory joint disease gout proposed 
that aggregated NETs promote the resolution of PMN-driven inflammation, by 
degrading cytokines and chemokines and disrupting PMN recruitment and 
activation172. Thus, as the mode of cell death during resolution may be dependent on 
tissue environmental cues, it may also be tissue- and disease-specific.  
 
Box 3 | Challenges with translation into humans  
Animal models of inflammation and resolution (Box 4) have generated invaluable 
information on cell trafficking, cell clearance as well as the receptors and soluble 
mediators that control these processes; howvever, their relevance to human 
physiology and pathology has been questioned. The disparity between rodent and 
human experimental medicine was exemplified by a recent report showing that 
although acute inflammatory stimuli such as trauma, burns and endotoxin result in 
highly stereotyped genomic responses in humans, the equivalent responses in 
mouse models were not comparable173. Although controversial174, 175, Seok et al. 
called for “higher priority for translational medical research to focus on the more 
complex human conditions rather than relying on mouse models to study human 
inflammatory diseases”173. This is not without difficulty. Studying fundamental 
resolution biology in the clinical population is challenging, being complicated by 
demographic variables, polypharmacy, sample timing with regards to disease stage 
and other factors. Further, there are inevitably complex interactions between 
concomitant pathologies and resolution pathways, as exemplified by atherosclerosis 
and hyperglycaemia.  
 
Atherosclerosis is initiated by shear stress and the deposition of cholesterol-rich 
lipoproteins in the artery wall with the resultant entry of inflammatory leukocytes into 
lesions. This process, if left un-checked, impedes resolution, and enables disease 
progress to endothelial dysfunction, vascular smooth muscle proliferation and 
associated clinical sequelae176. Reducing plasma low-density lipoprotein cholesterol 
levels using rosuvastatin or atorvastatin can promote regression of atherosclerotic 
lesions in humans177 — in other words, removing the inciting stimulus is sufficient to 
help resolve this multifactorial chronic inflammatory disease. However, this statin-
mediated effect is either obscured or negated in individuals with type 1 or type 2 
diabetes. In murine models, hyperglycaemia is associated with increased numbers of 
circulating monocytes — especially inflammatory Ly6C+ monocytes178 — and 
PMNs179, which leads to their increased, proportional entry into plaques and 
consequent accelerated lesion progression. This appears to be replicated clinically: 
compared with individuals who have atherosclerosis alone, individuals with 
atherosclerosis and diabetes show impaired regression in response to cholesterol-
reducing therapies180, emphasizing the challenge of attempting to pharmacologically 
resolve clinical disease.  
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Perhaps the optimal pragmatic course for demonstrating the potential of pro-
resolution strategies would be a combination of studies Blume, K.E. et al. Cell surface 
externalization of annexin A1 as a failsafe mechanism preventing inflammatory responses during 
secondary necrosis. J Immunol 183, 8138-47 (2009). on healthy humans and rodents. To this 
end, several human models to explore innate immunity and inflammation are now 
available. Skin represents a reproducible and clinically-relevant window into the 
human immune system, with multiple methods to elicit inflammation — including 
cantharidin181-184, which causes acantholysis. This sterile tissue injury model is 
driven by damage-associated molecular pattern molecules (DAMPs) such as 
purines, S100 proteins and nucleic acids. The elicited inflammatory response is 
characterized by rapid PMN infiltration followed by recruitment of macrophages and 
a smaller proportion of lymphocytes. Although responsive to many traditional anti-
inflammatories, the model’s utility is limited in temporal duration (<72hrs) by blister 
stability. Other models include intradermal injection of endotoxin185 or lung inhalation 
of endotoxin186. Both trigger a robust innate immune response that spontaneously 
resolves and may better faciliitate exploration of post-resolution processes, offering a 
more ‘physioloigical’ system. Akbar and colleagues have additionally characterized 
the adaptive immune responses to recall antigens, including tuberculin purified 
protein that was administered via intradermal injection and subsequent suction 
blister, as a means of understanding immunosenescence in aged human 
volunteers187, 188.   
 
Demonstration of the similarities of the fundamental biological processes that 
underlie resolution in these human models with those observed in animal studies to 
date will hopefully provide reassurance of their validity. Further development and 
appropriate selection of human inflammatory models, along with acquisition of 
dedicated clinical samples, will, however, be crucial in translating current theory to 
future therapy. 
 
Box 4 | Murine and zebrafish models 
In mice, the effects of putative and anti-inflammatory and pro-resolution drugs can be 
traced over time using the ‘industrial standard’ oxazalone ear-swelling (type IV 
hypersensitivity) and carrageenan-induced paw-swelling models. These models also 
enable each animal to serve as its own control, meaning smaller numbers of mice 
need be used — particularly useful when using precious transgenic mice or in quick 
proof-of-principle investigations. Whereas these models’ readouts centre on oedema 
formation, they may be complemented with peritonitis and pleuritis models that use 
sterile stimuli such as zymosan, which allow greater insight into leukocyte dynamics 
and access to inflammatory exudates that contain soluble mediators.  
 
It is important to bear in mind idiosyncratic features of individual models of different 
diseases in different species, genetic manipulations, and organs or tissues. For 
example, it is ill-advised to use transgenic mice with the air-pouch model, owing to 
the possibility that the intra-pouch fibro-vascular lining that is needed to enumerate 
the inflammatory response may be dependent on expression of the gene of interest 
during development, although this concern can be mitigated by using conditional 
knockouts.   
 
Originally, termination of PMN influx, efferocytosis and cytokine clearance were 
considered adequate metrics of resolution; however, these quickly became 
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insufficient17, 189. Quantitative indices such as Ψmax (the maximal number of PMNs 
present during the inflammatory response), Tmax (the time at which Ψmax occurs) and 
the resolution interval (Ri) from Tmax to T50 (when PMN numbers reach half Ψmax)126 
became useful when quantifying the effects of pharmacological intervention or 
genetic manipulation on resolution. In turn, a new, more-robust set of criteria will 
probably be required to assess the changes in the ability of resolution processes to 
bridge the gap between acute inflammation and adaptive immunity.  
 
Zebrafish can also be used in inexpensive high-throughput screening of pro-
resolution drugs. For example, tail fins can be surgically transected to cause a 
reproducible and robust inflammatory response that can be assessed by PMN 
counts or through fluorescence imaging of PMNs over time. In one study, injured 
zebrafish larvae with GFP-labelled PMNs were exposed to compounds from 4 hours 
post-injury (a time point when high numbers of PMNs have been recruited to the 
wound site), to 12 hours post injury (when inflammation resolution was only partially 
complete in controls)190. Tanshinone IIA, which is derived from a Chinese medicinal 
herb, potently induced inflammation resolution by inducing PMN apoptosis and 
promoting reverse migration of PMNs. Tanshinone IIA also blocked pro-inflammatory 
signals in the zebrafish, and its effects were conserved in human PMNs, supporting 
the translational potential of this drug and this screening strategy. 
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Figure 1. Resolution and adaptive immunity. We have recently shown4 that 
resolution is not the end of the immune response to infection or injury, but rather it 
acts as a bridge between innate and adaptive immunity, thereby adding a third 
phase to acute inflammation after acute and resolution — namely, post-resolution 
(a). Moreover, the idea that acute inflammation drives adaptive immuity also leads to 
an alternative explanation of the pathogenesis of some diseases that are driven by 
chronic inflammation (b). Specifically, diseases driven by ‘inflammation-gone-wrong’ 
may arise from incomplete resolution of the initial acute response that, in turn, does 
not fully engage an appropriate adaptive immune response that would otherwise 
lead to full resolution. Thus, although many early-phase Th-1-type cytokines have 
evolved to drive inflammation, their persistence may paradoxically derail resolution, 
resulting in impaired antigen clearance and the development of maladaptive 
immunity.  
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Figure 2. Acute inflammation and its resolution. Responses to infection or injury 
are characterized by the early and sequential release of ‘go signals’, including pro-
inflammatory cytokines and cell adhesion molecules, that collectively facilitate 
leukocyte migration into tissues. These events are counterbalanced by the 
concomitant release of ‘stop signals’, which serve to temper the severity of acute 
inflammation should it become too overexuberant and cause excessive tissue injury. 
These signals include IL-10, PGE2 and factors that control the magnitude of TLR and 
NFκ-B signalling. Once the injurious agent is removed, pathways of resolution are 
activated, and include removal of the inciting stimulus and destabilization of pro-
inflammatory mRNAs (via expression of SRC3, TTP and ZC3H12A). The latter, 
along with active pro-inflammatory mediator clearance (for example, through D6-
mediated scavenging) and leukocyte death followed by efferocytosis, leads to tissue 
resolution. These pro-resolution events were once thought to result in inflamed 
tissues reverting back to homeostasis; however, it is likely that they are a prelude to 
priming of adaptive immunity and also impact on the imprinting of innate immunity. 
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Figure 3. Anti-inflammation versus pro-resolution strategies. It is important to 
emphasise the difference between (a) anti-inflammation and (b) pro-resolution. The 
former describes the inhibition of factors that drive inflammation, including vasoactive 
amines, eicosanoids, cytokines, chemokines and cell adhesion molecules. Among 
the pharmacological tools developed to achieve this clinically are nonsteroidal anti-
inflammatory drugs and biologicals such as anti-TNF therapies. This form of 
intervention dampens inflammation from the onset with or without accelerated 
resolution. Pro-resolution, on the other hand, describes enhancing or promoting the 
factors essential for removal of the inciting stimulus as well as dampening pro-
inflammatory signalling, followed by leukocyte clearance. It is envisioned that pro-
resolution therapies will not necessarily affect onset but will accelerate resolution.  
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Lipids 
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Lipoxin A4/B4 FPR2/ALX, GPR32 + +    + + 191-194 
Resolvin E1 BLT1, Chem R23 +  +   + + 195-197 
Resolvin D1 FPR2/ALX, GPR32 +  +   + + 198 
Resolvin D2 GPR18 +     +  128 
Maresins Not known +     +  199-202 
Protectin D1 Not known +    +   203, 204 
PGD2 DP1, DP2 +       133, 135, 205-207 
15-deoxy12-14PGJ2 PPAR +  +     
133, 135, 207-209 
Protein 
D6 –  +      210, 211 
Annexin A1/Lipo- 
cortin A1 
FPR2/ALX +     + + 212-214 
Galectin 1 CD2, CD3, CD7, 
CD43, CD45 
+    + +  215-217 
Galectin 9          
Ac2-26 FPR1, FPR2/ALX +     +  212-214, 218-220 
AlphaMSH MC3R +     +  221-224 
Chemerin 15 ChemR23/CMKLR1 +     +  225-227 
Gaseous mediators 
CO –        228-230 
H2S – +  +  +  + 147, 149 
Changes in intracellular signalling pathways 
↓NF-κB –     +  + 74, 80, 231, 232 
↓CDKs –     +   90, 130, 233 
↓PI3K –     +   73, 76, 80, 234 
↓ERK1 or ERK2 –     +   84, 200, 235 
cAMP  –     + + + 73, 79, 236-238 
Intracellular regulators 
LRRC33 –   +     31 
RP105 –   +     32 
Cylindromatosis –   +     33 
TTP –    +    38, 40, 42, 239 
MicroRNAs (miR-
146, miR-21) 
–    +    55, 60 
Others 
Adenosine – +      + 240, 241 
          
 
 
 
 
 
 
Glossary 
Non-phlogistic 
In an anti-inflammatory manner. 
 
Efferocytosis 
The removal of effete, mainly apoptotic, cells by professional phagocytes, especially 
macrophages.  
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Eicosanoids 
20-carbon structures that are derived from arachidonic acid. Examples include the 
prostaglandins and leukotrienes.  
 
 
Adenine- or uridine-rich elements 
(AREs). 3′ untranslated regions of mRNA that recruit destabilizing factors and 
translational silencers. 
 
microRNA 
(miRNA) A small non-coding RNA molecule containing about 21-22 nucleotides, 
which function by base-pairing with complementary sequences within mRNA 
molecules. 
 
Polysensitization 
A phenomenon in which sensitization to one allergen favours sensitization to other 
environmental allergens.  
 
Macrophage plasticity 
The ability of macrophages to alter or adapt their biological function commensurate 
with the inflammatory environment they inhabit. 
 
Granulocytes 
White blood cells that are characterized by granules in their cytoplasm. These 
include PMNs, eosinophils, basophils and mast cells. 
 
Stress granules 
Sites where untranslated mRNAs accumulate in cells that have been subjected to 
adverse environmental conditions.  
 
Exudate 
Cells and fluid that accumulate outside of blood vessels or an organ during 
inflammation.  
 
Acantholysis 
Pathological separation of the epidermis from the dermis.  
 
Zymosan 
A ligand found on the surface of fungi. It binds to TLR2 and Dectin receptors  
 
Co-inhibitory molecules 
Molecules belonging to the immunoglobulin superfamily or the tumour necrosis factor 
receptor superfamily that inhibit T cell receptor-mediated responses. 
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Key point summary 
1. Inflammation is a beneficial process, designed to contain and eradicate threats to the 
host organism. Dysregulation of the magnitude or duration of inflammation 
contributes to multiple pathologies. 
 
2. Traditionally, drugs have been designed to reduce inflammation. Some such 
approaches — for example, non-steroidal anti-inflammatory drugs or pro-
inflammatory cytokine ablation —achieve this by targeting factors that drive 
inflammation; others — for example, glucocorticoids — are directly anti-
inflammatory. 
 
3. Active, specialized pathways bring about the resolution of inflammation. These 
involve discrete mediators and distinct cell phenotypes that act in a non-phlogistic 
manner to promote the clearance of inflammatory cells and a return to local tissue 
homeostasis.  
 
4. Recent advances in our understanding of the central processes in the resolution of 
inflammation — including pro-inflammatory mediator catabolism, dampening of 
downstream signalling, apoptosis and efferocytosis of inflammatory cells, and their 
regulation — permit targeted pharmacological interventions to promote inflammatory 
resolution. 
 
5. The development of drugs that promote or mimic the mode of action of endogenous 
pro-resolution pathways may afford a novel complementary, or potentially superior 
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strategy, to traditional options — regulating inflammation and restoring function, not 
merely suppressing inflammation. 
 
6. Recent discoveries suggest the innate immune response, and in particular its 
resolution, may modulate the subsequent development of adaptive immunity, and so 
may afford further therapeutic targets. Multiple challenges remain in developing 
human models of inflammatory resolution and in translating murine discoveries to 
date into drugs for man. 
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